CN102093967B - A strain of Enterococcus faecium derived from mink and its application - Google Patents
A strain of Enterococcus faecium derived from mink and its application Download PDFInfo
- Publication number
- CN102093967B CN102093967B CN2010105696124A CN201010569612A CN102093967B CN 102093967 B CN102093967 B CN 102093967B CN 2010105696124 A CN2010105696124 A CN 2010105696124A CN 201010569612 A CN201010569612 A CN 201010569612A CN 102093967 B CN102093967 B CN 102093967B
- Authority
- CN
- China
- Prior art keywords
- enterococcus faecium
- mdf1104
- mink
- application
- faecium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000194031 Enterococcus faecium Species 0.000 title claims abstract description 45
- 241000772415 Neovison vison Species 0.000 title claims abstract description 16
- 230000037406 food intake Effects 0.000 claims description 2
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 21
- 230000015556 catabolic process Effects 0.000 abstract description 11
- 235000012000 cholesterol Nutrition 0.000 abstract description 10
- 238000006731 degradation reaction Methods 0.000 abstract description 10
- 235000021050 feed intake Nutrition 0.000 abstract description 8
- 206010012735 Diarrhoea Diseases 0.000 abstract description 7
- 238000000855 fermentation Methods 0.000 abstract description 6
- 230000004151 fermentation Effects 0.000 abstract description 6
- 230000036737 immune function Effects 0.000 abstract description 6
- 150000001720 carbohydrates Chemical class 0.000 abstract description 5
- 241000282339 Mustela Species 0.000 abstract description 3
- 230000001932 seasonal effect Effects 0.000 abstract description 3
- 239000012050 conventional carrier Substances 0.000 abstract description 2
- 235000021051 daily weight gain Nutrition 0.000 abstract description 2
- 238000004321 preservation Methods 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 241000894006 Bacteria Species 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000002354 daily effect Effects 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 238000001514 detection method Methods 0.000 description 6
- 230000000529 probiotic effect Effects 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 241000194033 Enterococcus Species 0.000 description 4
- 235000021052 average daily weight gain Nutrition 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XLSLFPQAPYONPW-WHUHBCJBSA-N (2s,3s,4s,5r,6r)-6-[(r)-cyano(phenyl)methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H](C#N)C1=CC=CC=C1 XLSLFPQAPYONPW-WHUHBCJBSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UNGXBWFICNLIRX-UHFFFAOYSA-N Laetrile Natural products NCC(OC1OC(C(O)C(O)C1O)C(=O)O)c2ccccc2 UNGXBWFICNLIRX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004767 rumen Anatomy 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000010119 systemic immune function Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种屎肠球菌菌株及其应用。具体涉及的屎肠球菌MDF1104,专利保藏号CGMCC No.4237。还涉及屎肠球菌MDF1104在碳水化合物发酵,胆固醇降解方面的应用;尤其涉及屎肠球菌MDF1104单独应用或与常规载体组合可以增加水貂采食量,日增重,增强机体免疫机能,并且可以预防或治疗水貂季节性腹泻。The invention relates to an Enterococcus faecium strain and application thereof. Specifically related to Enterococcus faecium MDF1104, patent preservation number CGMCC No.4237. It also relates to the application of Enterococcus faecium MDF1104 in carbohydrate fermentation and cholesterol degradation; especially related to the application of Enterococcus faecium MDF1104 alone or in combination with conventional carriers can increase mink feed intake, daily weight gain, enhance the immune function of the body, and can prevent or Treating seasonal diarrhea in minks.
Description
技术领域 technical field
本发明涉及一株从水貂体内分离得到的屎肠球菌,并特别涉及其在毛皮动物日粮中的应用。The invention relates to a strain of Enterococcus faecium isolated from mink, and particularly relates to its application in the ration of fur animals.
技术背景 technical background
微生态制剂是通过改善寄主肠道菌群平衡而发挥有益作用的活的益生菌制剂,以其绿色安全、无毒副作用、无残留的优点逐步成为替代抗生素类添加剂的主力军。肠球菌属细菌在自然界中分布很广,在一些蔬菜和植物中常见,也是人和动物消化道内正常存在的一种微生物,主要定植在回肠和结肠部位。肠球菌作为益生菌的应用主要集中在粪肠球菌和屎肠球菌,屎肠球菌属于乳酸菌,由于它生长速度快,有较好的黏附能力,能产生乳酸及一些抗菌物质,被广泛的用作为益生菌制剂。研究表明屎肠球菌组成的益生菌可提高幼年畜禽的体增重,提高营养物质消化率,改善饲料报酬,减少腹泻比率,缓解应激状况,降低死亡率。肠球菌除具备以上功能外,还可直接参与胆固醇的代谢,并对异常代谢进行调整,使之恢复正常。肠球菌作为微生态制剂被广泛的应用于肉鸡、育肥猪、育肥牛、仔猪和奶牛生产中。此外,微生态制剂对机体有明显的免疫促进作用,可以促进新生儿肠道免疫系统的发育,也可以促进肠道黏膜局部和系统免疫功能,对特异性和非特异性免疫应答均有调节作用,维持机体在健康状态时免疫功能的正常水平。尽管益生菌具有以上众多免疫调节作用,但对菌种来说,不仅种属之间免疫效果有差异,而且菌株与菌株之间也有不同。此外,摄入时间、供给方式和添加量等方面对免疫调节效果也有影响。宿主也因品种、年龄、生理状况、生活环境的差异,而产生不同的效果。Microecological preparations are live probiotic preparations that play a beneficial role by improving the balance of the host's intestinal flora. With their advantages of green safety, no toxic side effects, and no residues, they have gradually become the main force to replace antibiotic additives. Bacteria of the genus Enterococcus are widely distributed in nature and are common in some vegetables and plants. They are also a type of microorganisms that normally exist in the digestive tract of humans and animals, and are mainly colonized in the ileum and colon. The application of Enterococcus as a probiotic mainly focuses on Enterococcus faecalis and Enterococcus faecium. Enterococcus faecium belongs to lactic acid bacteria. Because it grows fast, has good adhesion ability, and can produce lactic acid and some antibacterial substances, it is widely used as Probiotic preparations. Studies have shown that the probiotics composed of Enterococcus faecium can increase the body weight of young livestock and poultry, improve the digestibility of nutrients, improve feed remuneration, reduce the rate of diarrhea, relieve stress, and reduce mortality. In addition to the above functions, Enterococcus can also directly participate in the metabolism of cholesterol, and adjust the abnormal metabolism to make it return to normal. As a microecological agent, Enterococcus is widely used in the production of broiler chickens, fattening pigs, fattening cattle, piglets and dairy cows. In addition, probiotics have obvious immune-promoting effects on the body, can promote the development of the neonatal intestinal immune system, and can also promote the local and systemic immune function of the intestinal mucosa, and can regulate both specific and non-specific immune responses. Maintain the normal level of immune function when the body is in a healthy state. Although probiotics have many of the above-mentioned immunomodulatory effects, for bacterial species, not only are there differences in immune effects between species, but also differences between strains. In addition, the intake time, supply method and addition amount also have an impact on the immune regulation effect. The host also produces different effects due to differences in species, age, physiological conditions, and living environments.
屎肠球菌在环境中广泛存在,并且属于肠道共生菌,在很多动物新出生的2~3d内占优势地位,并且是一种兼性厌氧的乳酸菌,非常适合于生产和应用。目前市场上已有很多产品中包含屎肠球菌菌株,如韩国的“妈咪爱”,德国和瑞典生产的益生菌制品Ventrux、Bioflorin和Fiormil等,其活菌数大约为108-9个/g产品,目前含屎肠球菌的制品也已被广泛的应用于动物生产中,如韩国生产的饲料添加剂“优比他”等。围产期奶牛饲喂含有屎肠球菌的直接饲用微生物能够促进草料在瘤胃中消化,增加产奶量。肉牛饲喂含有屎肠球菌的直接饲用微生物能够促进肉牛适应高精料日粮,防止酸中毒。应用得当的屎肠球菌不仅可以促进营养物质消化吸收,降低血清胆固醇含量,维持肠道菌群平衡,还可以调节机体免疫功能,刺激胸腺、脾脏和法氏囊等免疫器官的发育,增强巨噬细胞的吞噬活性,活化肠道相关淋巴组织,促进免疫球蛋白A的生成,调节机体的免疫功能。Enterococcus faecium exists widely in the environment and belongs to the intestinal symbiotic bacteria. It is dominant in many animals within 2 to 3 days after birth, and is a facultative anaerobic lactic acid bacteria, which is very suitable for production and application. At present, there are many products on the market that contain Enterococcus faecium strains, such as South Korea's "Mami Love", probiotic products Ventrux, Bioflorin and Fiormil produced in Germany and Sweden, etc., the number of live bacteria is about 10 8-9 / g products, currently products containing Enterococcus faecium have also been widely used in animal production, such as the feed additive "Ubita" produced in South Korea. Feeding direct-fed microorganisms containing Enterococcus faecium to dairy cows during the transition period can promote forage digestion in the rumen and increase milk production. Feeding beef cattle direct feed microorganisms containing Enterococcus faecium can promote the adaptation of beef cattle to high-concentrate diets and prevent acidosis. Properly applied Enterococcus faecium can not only promote the digestion and absorption of nutrients, reduce serum cholesterol levels, maintain the balance of intestinal flora, but also regulate the immune function of the body, stimulate the development of immune organs such as the thymus, spleen and bursa of Fabricius, and enhance macrophages. Phagocytic activity of cells, activation of intestinal-associated lymphoid tissue, promotion of immunoglobulin A production, regulation of immune function of the body.
关于乳酸菌添加剂,在毛皮动物生产中的研究与应用,国内外研究较少,本发明基于益生菌添加剂的益生作用效果,提出了一株来源于毛皮动物体内的安全,稳定,高活性的乳酸菌,并对其优势作用进行检测。Regarding the lactic acid bacteria additive, the research and application in the production of fur animals is less researched at home and abroad. Based on the probiotic effect of the probiotic additive, the present invention proposes a safe, stable and highly active lactic acid bacteria derived from fur animals. and test its advantages.
发明内容 Contents of the invention
从健康成年水貂肠道内分离乳酸菌,取小肠内容物20g,加入100ml无菌水中,摇床震荡30min,使颗粒物质充分溶解,梯度稀释,利用倾注培养法进行分离培养,37℃培养72h选择具有溶钙圈的菌落,采用平板划线的方式纯化,纯化3-4代,镜检,将纯化后的乳酸菌接入MRS液体培养基中,检测其微生物学特性,如形态学、生理学特性(表1)以及糖分解代谢(表2)的能力,检测其体外培养对胆固醇的降解功能(表3)。进行小鼠安全性(表4)检测以及对水貂生产性能(表5)的影响。Isolate lactic acid bacteria from the intestinal tract of healthy adult mink, take 20g of small intestinal content, add 100ml of sterile water, and shake on a shaker for 30min to fully dissolve the particulate matter, gradient dilution, isolation and culture by pouring culture method, 37 ° C for 72 hours to select those with soluble bacteria The colony of the calcium circle was purified by streaking on a plate, purified for 3-4 generations, and examined under a microscope. The purified lactic acid bacteria were inserted into the MRS liquid medium to detect their microbiological characteristics, such as morphological and physiological characteristics (Table 1 ) and the ability of sugar catabolism (Table 2), and the degradation function of cholesterol in vitro culture (Table 3). Carry out mouse safety (Table 4) detection and the impact on mink production performance (Table 5).
该屎肠球菌MDF1104已于2010年10月21日于中国微生物菌种保藏管理委员会普通微生物中心(地址:中国北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所)保藏,保藏号CGMCC No.4237。其分类命名为:屎肠球菌,拉丁名:Enterococcusfaecium。The Enterococcus faecium MDF1104 was preserved on October 21, 2010 in the General Microbiology Center of the China Committee for the Collection of Microbial Cultures (Address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, China, Institute of Microbiology, Chinese Academy of Sciences) No. CGMCC No.4237. Its classification is named: Enterococcus faecium, Latin name: Enterococcusfaecium.
附图说明 Description of drawings
图1屎肠球菌MDF1104在体外培养条件下对胆固醇的降解,横坐标为培养时间(单位:小时),纵坐标为降解率(%)。Fig. 1 Degradation of cholesterol by Enterococcus faecium MDF1104 under in vitro culture conditions, the abscissa is the culture time (unit: hour), and the ordinate is the degradation rate (%).
下面结合实施例和图进一步说明本发明:Below in conjunction with embodiment and figure further illustrate the present invention:
实施例ⅠExample I
屎肠球菌MDF1104形态学观察、显微镜检以及生理生化指标检测Morphological observation, microscopic examination and detection of physiological and biochemical indicators of Enterococcus faecium MDF1104
无菌条件下用接种环挑取培养18-24h的屎肠球菌MDF1104,涂于干净的载玻片上,制片,革兰氏染色进行形态学及染色结果观察。无菌条件下将屎肠球菌接种于相应的培养基或培养条件下,进行生理生化指标的检测观察,检测结果见表1Under sterile conditions, use an inoculation loop to pick up Enterococcus faecium MDF1104 cultured for 18-24 hours, smear it on a clean glass slide, make slides, and observe the morphology and staining results with Gram staining. Enterococcus faecium was inoculated in the corresponding medium or culture conditions under aseptic conditions, and the physiological and biochemical indicators were detected and observed. The test results are shown in Table 1
表1屎肠球菌MDF1104形态学与理化试验结果Table 1 Morphological and physicochemical test results of Enterococcus faecium MDF1104
实施例ⅡExample II
屎肠球菌MDF1104对不同碳水化合物发酵活性检测Detection of different carbohydrate fermentation activities of Enterococcus faecium MDF1104
无菌条件下,用接种环挑取少许生长旺盛的,培养18-24h的屎肠球菌MDF1104,接种入北京陆桥技术有限责任公司生产的不同糖发酵管内,37℃恒温培养18-24h,观察发酵液颜色变化,以判断对不同碳水化合物的发酵情况。Under sterile conditions, use an inoculation loop to pick a small amount of Enterococcus faecium MDF1104 that grows vigorously, and culture it for 18-24 hours, inoculate it into different sugar fermentation tubes produced by Beijing Land Bridge Technology Co., Ltd., and culture it at a constant temperature of 37°C for 18-24 hours, and observe the fermentation The color of the liquid changes to judge the fermentation of different carbohydrates.
表2屎肠球菌MDF1104不同碳水化合物发酵活性Table 2 Fermentation activity of different carbohydrates of Enterococcus faecium MDF1104
由表1,2可知,屎肠球菌MDF1104,革兰氏染色阳性,可在较广泛温度范围内生长,24h培养产酸能力强,可广泛利用碳水化合物产生能量,是一株性状优良的乳酸菌。It can be seen from Tables 1 and 2 that Enterococcus faecium MDF1104 is Gram-positive, can grow in a wide temperature range, has strong acid production ability after 24-hour culture, and can widely use carbohydrates to generate energy. It is a lactic acid bacterium with excellent characteristics.
实施例ⅢExample III
屎肠球菌MDF1104在体外培养过程中对胆固醇的降解作用Cholesterol degradation by Enterococcus faecium MDF1104 in vitro
将纯化培养后的屎肠球菌MDF1104,接种入新配制并灭菌的MRS液体培养基中,37℃培养18-24小时,每隔四小时取样,离心取上清,利用邻苯二甲醛法测定24h内乳酸菌对胆固醇的降解能力。Inoculate the purified and cultivated Enterococcus faecium MDF1104 into the newly prepared and sterilized MRS liquid medium, culture at 37°C for 18-24 hours, take samples every four hours, centrifuge to get the supernatant, and use the o-phthalaldehyde method to determine The ability of lactic acid bacteria to degrade cholesterol within 24 hours.
表3屎肠球菌MDF1104对胆固醇的降解率Table 3 Degradation rate of Enterococcus faecium MDF1104 to cholesterol
由表3和附图1可知,屎肠球菌MDF1104,在体外培养条件下可以降解胆固醇,并且在整个培养期均可高效降解,平均降解率达到33.23%,在对数分裂期达到最高为38.45%,由此说明水貂源屎肠球菌MDF1104对胆固醇有较好的降解性,并且在体外培养期内其降解效率下降不大,由此也说明MDF1104对高胆固醇食品或饲料的降解具有其独特优势。It can be seen from Table 3 and Figure 1 that Enterococcus faecium MDF1104 can degrade cholesterol under in vitro culture conditions, and can be degraded efficiently throughout the culture period, with an average degradation rate of 33.23%, and a maximum of 38.45% in the logarithmic division phase , which shows that the mink-derived Enterococcus faecium MDF1104 has a good degradability to cholesterol, and its degradation efficiency does not decrease much during the in vitro culture period, which also shows that MDF1104 has its unique advantages in the degradation of high-cholesterol food or feed.
实施例ⅣExample IV
屎肠球菌MDF1104对小白鼠安全性及生产性能指标的影响Effects of Enterococcus faecium MDF1104 on the safety and production performance indexes of mice
将屎肠球菌MDF1104接入10ml液体培养基中,接种量1%,37℃培养18h,5000rmp/min离心10分钟,用生理盐水稀释为107cfu/ml和109cfu/ml。选取健康的成年昆明系小白鼠,每组15只,实验组每天每只经口灌注不同浓度的MDF1104稀释液0.3ml,对照组每日灌注等量的生理盐水,连续灌注20天,观察10天,每天进行观察,记录采食情况,体重情况。定期称重,每日监测采食情况,30d时进行屠宰实验,称量胸腺,脾脏重量,计算免疫器官指数。Inoculate Enterococcus faecium MDF1104 into 10ml of liquid medium with an inoculum size of 1%, culture at 37°C for 18 hours, centrifuge at 5000rmp/min for 10 minutes, and dilute to 10 7 cfu/ml and 10 9 cfu/ml with physiological saline. Select healthy adult Kunming mice, 15 mice in each group, each mouse in the experimental group was orally perfused with 0.3ml of MDF1104 dilution solution of different concentrations every day, and the control group was perfused with the same amount of normal saline every day, continuous perfusion for 20 days, and observation for 10 days , observe every day, record the situation of food intake and body weight. Regular weighing, daily monitoring of feed intake, slaughter experiment at 30 days, weighing of thymus, spleen weight, calculation of immune organ index.
表4.屎肠球菌MDF1104对小白鼠安全性及生产性能指标影响Table 4. Effect of Enterococcus faecium MDF1104 on the safety and production performance indicators of mice
由表4可知,水貂源的屎肠球菌MDF1104,以不同剂量灌注小鼠,未有小鼠死亡,并且添加MDF1104组小鼠的日采食量以及平均日增重均显著高于对照组,免疫器官指数低剂量组低于对照组,高剂量组略高于对照组。由此可知,屎肠球菌MDF1104,对小白鼠无致死性。并且对小白鼠的日增重及平均日采食量具有促进作用,并且高剂量组具有促进小鼠免疫功能的作用。It can be seen from Table 4 that the mice were perfused with different doses of Enterococcus faecium MDF1104 from mink, and no mice died, and the daily feed intake and average daily weight gain of the mice in the MDF1104 group were significantly higher than those in the control group. The organ index of the low-dose group was lower than that of the control group, and that of the high-dose group was slightly higher than that of the control group. It can be known that Enterococcus faecium MDF1104 is not lethal to mice. And it can promote the daily weight gain and average daily feed intake of mice, and the high-dose group can promote the immune function of mice.
实施例ⅤExample V
屎肠球菌MDF1104对水貂生产性能的影响Effect of Enterococcus faecium MDF1104 on the performance of mink
将屎肠球菌按1%的接种量,接入液体培养基中,37℃发酵24h,选取健康的育成期水貂,每组20只,试验组每天每只随饲料给饲109cfu/g干物质的屎肠球菌MDF1104,对照组不添加,定期称重,每日监测采食情况,跟踪每组水貂腹泻情况,连续饲喂30天,屠宰,称量免疫器官重量,计算免疫器官指数。Inoculate Enterococcus faecium into liquid culture medium at 1% inoculum amount, ferment at 37°C for 24 hours, select healthy minks in the breeding period, 20 for each group, and feed each mink with
表5屎肠球菌MDF1104对水貂生产性能的影响Table 5 Effect of Enterococcus faecium MDF1104 on mink performance
由表5可知,在育成期水貂日粮中添加屎肠球菌MDF1104,可以降低在8月末到9月初期间水貂季节性腹泻的发病率,与对照组相比,腹泻率下降40%,死亡率下降10%,可明显提高水貂日采食量4%以上,平均日增重速度增加约5%,免疫器官指数略有增加。It can be seen from Table 5 that adding Enterococcus faecium MDF1104 to the mink diet during the breeding period can reduce the incidence of seasonal diarrhea in mink during the period from the end of August to the beginning of September. Compared with the control group, the diarrhea rate decreased by 40%, and the mortality rate decreased. 10%, can significantly increase the mink daily feed intake by more than 4%, the average daily weight gain rate increases by about 5%, and the immune organ index increases slightly.
结论in conclusion
上述结果表明,本发明所涉及的屎肠球菌MDF1104,可以增加小鼠及水貂的日采食量及日增重,增强动物的免疫机能,屎肠球菌MDF1104单独应用或者与常规载体组合,可以预防水貂季节性腹泻的发生,改善动物的生产性能。The above results show that Enterococcus faecium MDF1104 involved in the present invention can increase the daily feed intake and daily gain of mice and minks, and enhance the immune function of animals. Enterococcus faecium MDF1104 can be used alone or combined with conventional carriers to prevent Occurrence of seasonal diarrhea in mink, improved animal performance.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105696124A CN102093967B (en) | 2010-12-02 | 2010-12-02 | A strain of Enterococcus faecium derived from mink and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010105696124A CN102093967B (en) | 2010-12-02 | 2010-12-02 | A strain of Enterococcus faecium derived from mink and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102093967A CN102093967A (en) | 2011-06-15 |
| CN102093967B true CN102093967B (en) | 2013-01-30 |
Family
ID=44127234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105696124A Expired - Fee Related CN102093967B (en) | 2010-12-02 | 2010-12-02 | A strain of Enterococcus faecium derived from mink and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102093967B (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
| US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
| US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
| US12048720B2 (en) | 2017-06-14 | 2024-07-30 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104862254B (en) * | 2015-05-26 | 2018-02-16 | 北京好实沃生物技术有限公司 | One Enterococcus faecalis HEW A588 and its application |
| CN105733977B (en) * | 2016-01-27 | 2019-06-14 | 南昌大学 | Probiotic Feed Additives |
| CN105733978B (en) * | 2016-01-27 | 2019-04-12 | 南昌大学 | One Enterococcus faecalis WEFA23 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005026269A1 (en) * | 2003-09-04 | 2005-03-24 | Mcdaniel C Steven | Microorganism coating components, coatings, and coated surfaces |
| CN101531986A (en) * | 2008-07-23 | 2009-09-16 | 中国农业科学院特产研究所 | Recombinant strain of mink IFN-Gamma gene |
| CN101601442A (en) * | 2008-11-05 | 2009-12-16 | 中国农业科学院特产研究所 | 1% special compound premix for mink |
-
2010
- 2010-12-02 CN CN2010105696124A patent/CN102093967B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005026269A1 (en) * | 2003-09-04 | 2005-03-24 | Mcdaniel C Steven | Microorganism coating components, coatings, and coated surfaces |
| CN101531986A (en) * | 2008-07-23 | 2009-09-16 | 中国农业科学院特产研究所 | Recombinant strain of mink IFN-Gamma gene |
| CN101601442A (en) * | 2008-11-05 | 2009-12-16 | 中国农业科学院特产研究所 | 1% special compound premix for mink |
Cited By (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11013773B2 (en) | 2011-07-14 | 2021-05-25 | 4D Pharma Research Limited | Lactic acid bacterial strains |
| US11266698B2 (en) | 2011-10-07 | 2022-03-08 | 4D Pharma Research Limited | Bacterium for use as a probiotic for nutritional and medical applications |
| US11414463B2 (en) | 2013-04-10 | 2022-08-16 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10851137B2 (en) | 2013-04-10 | 2020-12-01 | 4D Pharma Research Limited | Polypeptide and immune modulation |
| US10456444B2 (en) | 2014-12-23 | 2019-10-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US10973872B2 (en) | 2014-12-23 | 2021-04-13 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| US11723933B2 (en) | 2014-12-23 | 2023-08-15 | Cj Bioscience, Inc. | Composition of bacteroides thetaiotaomicron for immune modulation |
| US11389493B2 (en) | 2015-06-15 | 2022-07-19 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10780134B2 (en) | 2015-06-15 | 2020-09-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391130B2 (en) | 2015-06-15 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10500237B2 (en) | 2015-06-15 | 2019-12-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11273185B2 (en) | 2015-06-15 | 2022-03-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11040075B2 (en) | 2015-06-15 | 2021-06-22 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10736926B2 (en) | 2015-06-15 | 2020-08-11 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10322151B2 (en) | 2015-06-15 | 2019-06-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744167B2 (en) | 2015-06-15 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11433106B2 (en) | 2015-06-15 | 2022-09-06 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10493112B2 (en) | 2015-06-15 | 2019-12-03 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10864236B2 (en) | 2015-06-15 | 2020-12-15 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11331352B2 (en) | 2015-06-15 | 2022-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10610550B2 (en) | 2015-11-20 | 2020-04-07 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10471108B2 (en) | 2015-11-20 | 2019-11-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11058732B2 (en) | 2015-11-20 | 2021-07-13 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10744166B2 (en) | 2015-11-23 | 2020-08-18 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10391128B2 (en) | 2015-11-23 | 2019-08-27 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10583158B2 (en) | 2016-03-04 | 2020-03-10 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10960031B2 (en) | 2016-07-13 | 2021-03-30 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610548B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11224620B2 (en) | 2016-07-13 | 2022-01-18 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10967010B2 (en) | 2016-07-13 | 2021-04-06 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10610549B2 (en) | 2016-07-13 | 2020-04-07 | 4D Pharma Plc | Composition comprising bacterial strains |
| US10485830B2 (en) | 2016-12-12 | 2019-11-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10543238B2 (en) | 2016-12-12 | 2020-01-28 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US10898526B2 (en) | 2016-12-12 | 2021-01-26 | 4D Pharma Plc | Compositions comprising bacterial strains |
| US11123378B2 (en) | 2017-05-22 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11376284B2 (en) | 2017-05-22 | 2022-07-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11382936B2 (en) | 2017-05-22 | 2022-07-12 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US10987387B2 (en) | 2017-05-24 | 2021-04-27 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11123379B2 (en) | 2017-06-14 | 2021-09-21 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US12048720B2 (en) | 2017-06-14 | 2024-07-30 | Cj Bioscience, Inc. | Compositions comprising bacterial strains |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102093967A (en) | 2011-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102093967B (en) | A strain of Enterococcus faecium derived from mink and its application | |
| CN103598447B (en) | Non-antibiotic sucking pig milk replacer and preparation method | |
| CN101580799B (en) | A kind of compound probiotics and its application | |
| CN102409015B (en) | Composite micro-ecological preparation as well as premixed material and application of preparation in feed additive | |
| CN101671638B (en) | New strain of bifidobacterium and fermentative preparation method and application thereof | |
| CN101978849B (en) | Composite micro-ecological preparation and application thereof | |
| CN103966124A (en) | Compound microecological preparation and additive, as well as premix thereof | |
| CN106906154A (en) | One lactobacillus plantarum strain and its feed addictive and feed | |
| CN115094012B (en) | Preparation method and application of bacillus coagulans BC-HYC strain microbial inoculum | |
| CN102232479B (en) | A kind of preparation technology of bacillus feed additive | |
| WO2008023580A1 (en) | Animal feed additive | |
| CN102391962B (en) | Enterococcus faecium preparation agent and manufacturing technology thereof | |
| CN102965316B (en) | Bacteriocin containing class and the feed addictive of Pediococcus acidilactici, premix and batch | |
| CN101971920A (en) | Porcine lactobacillus reuteri lyophilized preparation and preparation method thereof | |
| Moarrab et al. | Effect of synbiotic on performance, intestinal morphology, fecal microbial population and blood metabolites of suckling lambs | |
| CN115925832A (en) | A kind of lactobacillus and its application in the prevention and control of livestock and poultry bacterial infection | |
| CN103320351B (en) | Lactococcus garvieae and biological feed-additive prepared therefrom | |
| CN104263683B (en) | Bacillus pumilus 315 and its application with prebiotic effect | |
| JP5499231B2 (en) | Animal feed composition containing Lactobacillus plantarum, combined animal feed containing the composition, and method for maintaining or growing the Lactobacillus plantarum in the animal intestine | |
| CN101904411A (en) | A kind of compound probiotics and its application | |
| CN110150488A (en) | A kind of pig feed additive and its preparation method and application | |
| CN105341425A (en) | A kind of pig feed containing antibacterial probiotics and its application | |
| CN117467584B (en) | A compound probiotic agent for improving cat intestinal health, preparation method and application | |
| CN106811429B (en) | Bacillus subtilis strain, application of feed additive thereof and feed | |
| CN105505808B (en) | A kind of compound micro-ecological preparation, additive, premix and batch |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP02 | Change in the address of a patent holder |
Address after: 130112 Jilin province Changchun Jingyue Economic Development Zone Industry Street No. 4899 Patentee after: INSTITUTE OF SPECIAL ANIMAL AND PLANT SCIENCES OF CAAS Address before: 132109 Jilin Province, Jilin city Changyi district left town Luming Street No. 15 Patentee before: INSTITUTE OF SPECIAL ANIMAL AND PLANT SCIENCES OF CAAS |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20200821 Address after: No.860, Weijia village, laodafang Town, Liaozhong District, Shenyang City, Liaoning Province, 110200 Patentee after: SHENYANG BOYANG FEED Co.,Ltd. Address before: 130112 Jilin province Changchun Jingyue Economic Development Zone Industry Street No. 4899 Patentee before: INSTITUTE OF SPECIAL ANIMAL AND PLANT SCIENCES OF CAAS |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130130 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |